Avadel Pharmaceuticals plc (AVDL)
NASDAQ$8.39
Market Cap
$810.72M
Sector
Healthcare
Industry
Drug Manufacturers—Specialty & Generic
Rank in Sector
158 of 924
Rank in Industry
8 of 56
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
AVDL Insider Trading Activity
AVDL Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $761,675 | 9 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Ende Eric J | director | 1 | $235,218 | 0 | $0 | $235,218 |
| Glass Geoffrey Michael | director | 1 | $199,641 | 0 | $0 | $199,641 |
| Divis Gregory J | Chief Executive Officer | 2 | $99,707 | 0 | $0 | $99,707 |
| Thornton Peter J. | director | 1 | $80,450 | 0 | $0 | $80,450 |
| MCHUGH THOMAS S | Chief Financial Officer | 2 | $76,451 | 0 | $0 | $76,451 |
| Palczuk Linda | director | 2 | $70,208 | 0 | $0 | $70,208 |
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Activity of Avadel Pharmaceuticals plc
Over the last 12 months, insiders at Avadel Pharmaceuticals plc have bought $761,675 and sold $0 worth of Avadel Pharmaceuticals plc stock.
On average, over the past 5 years, insiders at Avadel Pharmaceuticals plc have bought $949,222 and sold $1.52M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ende Eric J (director) — $235,218. Glass Geoffrey Michael (director) — $199,641. Divis Gregory J (Chief Executive Officer) — $99,707.
The last purchase of 5,000 shares for transaction amount of $39,640 was made by Palczuk Linda (director) on 2025‑01‑21.
List of Insider Buy and Sell Transactions, Avadel Pharmaceuticals plc
| 2025-01-21 | Palczuk Linda | director | 5,000 0.0052% | $7.93 | $39,640 | +1.17% | ||
| 2025-01-13 | Ende Eric J | director | 30,000 0.0321% | $7.84 | $235,218 | +2.30% | ||
| 2025-01-13 | Thornton Peter J. | director | 10,000 0.011% | $8.04 | $80,450 | +2.30% | ||
| 2024-12-13 | MCHUGH THOMAS S | Chief Financial Officer | 2,300 0.0024% | $10.44 | $24,019 | -21.46% | ||
| 2024-12-11 | MCHUGH THOMAS S | Chief Financial Officer | 5,000 0.0052% | $10.49 | $52,433 | -20.74% | ||
| 2024-12-10 | Glass Geoffrey Michael | director | 20,279 0.0208% | $9.84 | $199,641 | -17.90% | ||
| 2024-12-09 | Divis Gregory J | Chief Executive Officer | 402 0.0004% | $9.82 | $3,948 | -18.82% | ||
| 2024-12-06 | Palczuk Linda | director | 3,000 0.0031% | $10.19 | $30,568 | -17.15% | ||
| 2024-12-06 | Divis Gregory J | Chief Executive Officer | 9,598 0.0098% | $9.98 | $95,759 | -17.15% | ||
| 2024-01-16 | MCHUGH THOMAS S | Chief Financial Officer | 2,000 0.0021% | $14.50 | $29,000 | +0.20% | ||
| 2023-12-28 | Sale | McCamish Mark Anthony | director | 75,000 0.0802% | $14.53 | $1.09M | +2.67% | |
| 2023-08-14 | MCHUGH THOMAS S | Chief Financial Officer | 2,000 0.0027% | $14.45 | $28,900 | +4.62% | ||
| 2023-08-11 | Sale | McCamish Mark Anthony | director | 28,975 0.0388% | $14.93 | $432,614 | +0.07% | |
| 2023-08-10 | Divis Gregory J | Chief Executive Officer | 10,000 0.0128% | $13.20 | $131,997 | +8.34% | ||
| 2023-08-10 | Glass Geoffrey Michael | director | 14,000 0.0182% | $13.40 | $187,600 | +8.34% | ||
| 2023-05-18 | Ende Eric J | director | 13,000 0.0207% | $13.93 | $181,100 | +2.34% | ||
| 2023-05-09 | Palczuk Linda | director | 2,500 0.0038% | $14.76 | $36,900 | -6.91% | ||
| 2022-12-23 | Palczuk Linda | director | 2,000 0.0033% | $7.20 | $14,405 | +61.75% | ||
| 2022-11-29 | MCHUGH THOMAS S | Chief Financial Officer | 5,000 0.008% | $7.80 | $39,000 | +36.73% | ||
| 2022-11-22 | Ende Eric J | director | 20,000 0.0314% | $7.80 | $156,050 | +32.21% |
Total: 93
*Gray background shows transactions not older than one year
Insider Historical Profitability
20.9%
| Ende Eric J | director | 208900 0.2162% | $1.75M | 10 | 0 | +58.99% |
| Thornton Peter J. | director | 104055 0.1077% | $873,021.45 | 3 | 0 | +78.3% |
| MCHUGH THOMAS S | Chief Financial Officer | 87800 0.0909% | $736,642.00 | 9 | 0 | +35.58% |
| Glass Geoffrey Michael | director | 75904 0.0786% | $636,834.56 | 9 | 0 | +64.31% |
| Palczuk Linda | director | 67900 0.0703% | $569,681.00 | 7 | 0 | +51.27% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$910,099,463 | 123 | 11.52% | $2.54B | |
$187,390,806 | 89 | 12.63% | $381.87M | |
Avadel Pharmaceuticals plc (AVDL) | $12,681,496 | 70 | 20.90% | $810.72M |
$218,350,131 | 64 | 16.68% | $296.77M | |
$14,599,168 | 59 | 12.79% | $1.34B |
AVDL Institutional Investors: Active Positions
| Increased Positions | 91 | +48.66% | 11M | +15.18% |
| Decreased Positions | 80 | -42.78% | 6M | -8.7% |
| New Positions | 24 | New | 1M | New |
| Sold Out Positions | 41 | Sold Out | 3M | Sold Out |
| Total Postitions | 198 | +5.88% | 79M | +6.48% |
AVDL Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Janus Henderson Group Plc | $111,375.00 | 14.67% | 14.08M | +753,332 | +5.65% | 2024-12-31 |
| Gendell Jeffrey L | $50,074.00 | 6.59% | 6.33M | +524,995 | +9.04% | 2024-12-31 |
| Blackrock, Inc. | $43,026.00 | 5.67% | 5.44M | +182,404 | +3.47% | 2024-12-31 |
| Polar Capital Holdings Plc | $34,916.00 | 4.6% | 4.41M | -419,828 | -8.69% | 2024-12-31 |
| Two Seas Capital Lp | $33,985.00 | 4.47% | 4.3M | +2M | +90.63% | 2024-12-31 |
| Braidwell Lp | $32,476.00 | 4.28% | 4.11M | +716,787 | +21.15% | 2024-12-31 |
| Vanguard Group Inc | $31,270.00 | 4.12% | 3.95M | +90,147 | +2.33% | 2024-12-31 |
| Vivo Capital, Llc | $21,231.00 | 2.8% | 2.68M | 0 | 0% | 2024-12-31 |
| Citadel Advisors Llc | $20,515.00 | 2.7% | 2.59M | +234,992 | +9.96% | 2024-12-31 |
| Wealth Effects Llc | $18,542.00 | 2.44% | 2.34M | +110,359 | +4.94% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.